Rating Change
Oppenheimer reiterated its Outperform rating on Pelthos Therapeutics Inc. (NYSE:PTHS) on August 14, 2026.
reiterateNYSE:PTHS
Oppenheimer Reiterates Outperform Rating on Pelthos Therapeutics Inc. (PTHS)
Oppenheimer reiterated its Outperform rating on Pelthos Therapeutics Inc. (NYSE:PTHS) on August 14, 2026.
At publication ·
What changed
Pelthos Therapeutics Inc. (NYSE:PTHS) · reiterate
- Firm
- Oppenheimer
- Rating
- Outperform to Outperform
- Price at event
- $27.50
- Market capitalization
- $15.5M
At a glance
Key takeaways
- Oppenheimer reiterated an Outperform rating on Pelthos Therapeutics (PTHS) on August 14, 2026, with the stock trading at $27.50 and a market capitalization of $15.5 million.
Market Context
Pelthos Therapeutics Inc. operates in the Healthcare sector. The stock currently trades at $27.50 with a market capitalization of $15.5M. The stock has gained 44.7% over the past 52 weeks.
Analyst coverage from Oppenheimer provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Pelthos Therapeutics Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Pelthos Therapeutics Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 14, 2026 | Oppenheimer | Outperform | N/A |
| May 15, 2026 | Oppenheimer | Outperform | N/A |
| Apr 01, 2026 | Cantor Fitzgerald | Overweight | N/A |
| Mar 20, 2026 | Oppenheimer | Outperform | N/A |
| Mar 19, 2026 | HC Wainwright & Co. | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View PTHS Stock Page
Frequently Asked Questions
What does the Outperform rating mean for PTHS?
A rating of Outperform from Oppenheimer reflects the analyst's outlook on Pelthos Therapeutics Inc. (NYSE:PTHS). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the PTHS forecast page.